NBP

NovaBridge Biosciences

Price Chart

Latest Quote

$1.60

+0.07 (+4.90%)

Current Price

Previous Close	$1.53
Open	$1.50
Day High	$1.65
Day Low	$1.47
Volume	351,995

Fetched: 2026-06-23T19:08:21

Stock Information

Shares Outstanding	115.65M
Total Debt	$3.07M
Cash Equivalents	$210.84M
Net Income	$-88.34M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$186.19M
EPS (TTM)	$-0.48
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-21.58M
Income	$-88.34M
Book/sh	$2.00
Cash/sh	$1.82
Employees	30

Financial Ratios

Quick Ratio	7.91
Current Ratio	8.09
Debt/Eq	1.33

Returns & Margins

ROA	-24.90%
ROE	-40.89%

Ownership

Insider Ownership	14.41%
Institutional Ownership	39.90%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.52
P/B	0.80

Analyst Data

Recommendation	none
Target Price	$8.00

Technical Indicators

SMA20	$1.64
SMA50	$2.01
SMA200	$3.37
RSI	43.75
ATR	0.1254

Shares Float	64.48M
Short Float	6.89%
Short Ratio	2.91
Volatility	1.48
Rel Volume	0.79

Performance History

Week	+9.52%
Month	-9.55%
Quarter	-38.78%
6 Months	-59.34%
YTD	-62.30%
Year	-35.60%
3 Years	-47.73%
5 Years	-97.71%
10 Years	-87.12%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$1.61	424,100
2026-06-22	$1.53	272,800
2026-06-18	$1.50	648,900
2026-06-17	$1.57	714,000
2026-06-16	$1.51	684,800
2026-06-15	$1.47	567,800
2026-06-12	$1.49	358,800
2026-06-11	$1.47	442,600
2026-06-10	$1.53	435,900
2026-06-09	$1.59	402,100
2026-06-08	$1.56	458,200
2026-06-05	$1.64	598,500
2026-06-04	$1.80	277,500
2026-06-03	$1.75	562,400
2026-06-02	$1.71	756,500
2026-06-01	$1.71	606,100
2026-05-29	$1.84	361,200
2026-05-28	$1.87	591,600
2026-05-27	$1.87	856,800
2026-05-26	$1.86	713,400

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

📰 Latest News

Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth

Simply Wall St. • 2026-05-28T11:50:04Z

Amazon downgraded, Roblox upgraded: Wall Street's top analyst calls

The Fly • 2026-02-06T14:41:21Z

Insider Spends US$5.1m Buying More Shares In NovaBridge Biosciences

Simply Wall St. • 2026-02-05T12:07:30Z

Is There An Opportunity With NovaBridge Biosciences' (NASDAQ:NBP) 40% Undervaluation?

Simply Wall St. • 2026-01-08T17:13:46Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$632,000	$-1,551,000
Operating Revenue	$0	$0	$632,000	$-1,551,000
Reconciled Cost Of Revenue	-	-	$0	$3,947,792
Cost Of Revenue	-	-	$0	$3,947,792
Expenses
Total Expenses	$94,269,000	$51,426,000	$49,608,000	$51,527,000
Other Income Expense	$-1,682,000	$-5,756,000	$-42,535,000	$-92,976,000
Other Non Operating Income Expenses	$74,000	$637,000	$1,072,000	$412,000
Net Non Operating Interest Income Expense	$7,611,000	$7,486,000	$9,294,000	$4,954,000
Operating Expense	$94,269,000	$51,426,000	$49,608,000	$51,527,000
General And Administrative Expense	$31,364,000	$29,656,000	$28,160,000	$28,980,000
Other Operating Expenses	-	$-1,273,000	$-755,297	$-3,691,679
Interest Expense	-	-	$101,854	$1,304
Interest Expense Non Operating	-	-	$101,854	$1,304
Total Other Finance Cost	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-46,269,000	$-49,696,000	$-82,217,000	$-141,203,000
Net Interest Income	$7,611,000	$7,486,000	$9,294,000	$4,954,000
Interest Income	$7,611,000	$7,486,000	$9,294,000	$4,954,000
Normalized Income	$-44,513,000	$-44,341,000	$-50,014,000	$-119,692,250
Net Income From Continuing And Discontinued Operation	$-46,269,000	$-22,230,000	$-207,729,000	$-371,053,000
Total Operating Income As Reported	$-94,269,000	$-51,426,000	$-72,017,000	$-53,078,000
Net Income Common Stockholders	$-46,269,000	$-22,230,000	$-207,729,000	$-371,053,000
Net Income	$-46,269,000	$-22,230,000	$-207,729,000	$-371,053,000
Net Income Including Noncontrolling Interests	$-88,340,000	$-22,230,000	$-207,729,000	$-371,053,000
Net Income Discontinuous Operations	$0	$27,466,000	$-125,512,000	$-229,850,000
Net Income Continuous Operations	$-88,340,000	$-49,696,000	$-82,217,000	$-141,203,000
Pretax Income	$-88,340,000	$-49,696,000	$-82,217,000	$-141,100,000
Special Income Charges	$0	$-13,634,000	$-23,041,000	$0
Earnings From Equity Interest	$0	$-1,038,000	$-11,404,000	$-64,707,000
Interest Income Non Operating	$7,611,000	$7,486,000	$9,294,000	$4,954,000
Operating Income	$-94,269,000	$-51,426,000	$-48,976,000	$-53,078,000
Gross Profit	-	-	$3,899,783	$-36,061,629
Per Share
Diluted EPS	-	$-0.28	$-2.33	$-4.24
Basic EPS	-	$-0.28	$-2.33	$-4.24
Other
Tax Effect Of Unusual Items	$0	$0	$0	$-7,170,250
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-91,657,000	$-45,093,000	$-15,712,000	$-22,982,000
Total Unusual Items	$-1,756,000	$-5,355,000	$-32,203,000	$-28,681,000
Total Unusual Items Excluding Goodwill	$-1,756,000	$-5,355,000	$-32,203,000	$-28,681,000
Reconciled Depreciation	$856,000	$978,000	$1,061,000	$1,415,000
EBITDA (Bullshit earnings)	$-93,413,000	$-50,448,000	$-47,915,000	$-51,663,000
EBIT	$-94,269,000	$-51,426,000	$-48,976,000	$-53,078,000
Diluted NI Availto Com Stockholders	$-46,269,000	$-22,230,000	$-207,729,000	$-371,053,000
Minority Interests	$42,071,000	$0	$0	-
Tax Provision	$0	$0	$0	$103,000
Impairment Of Capital Assets	$0	$1,246,000	$23,041,000	$0
Gain On Sale Of Security	$-1,756,000	$8,279,000	$-9,162,000	$-28,681,000
Research And Development	$62,905,000	$21,770,000	$21,448,000	$22,547,000
Selling General And Administration	$31,364,000	$29,656,000	$28,160,000	$28,980,000
Other Gand A	$31,364,000	$29,656,000	$28,160,000	$28,980,000
Diluted Average Shares	-	$81,186,249	$88,654,063	$82,516,214
Basic Average Shares	-	$81,186,249	$88,654,063	$82,516,214
Other Special Charges	-	$12,388,000	-	-
Restructuring And Mergern Acquisition	-	$12,388,000	$0	$0
Gain On Sale Of Business	-	-	$-1,115,171	$0

Fetched: 2026-06-23

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$230,941,000	$201,160,000	$242,584,000	$380,971,983
Total Assets	$260,522,000	$212,680,000	$368,922,000	$590,446,132
Total Non Current Assets	$43,002,000	$35,987,000	$39,010,000	$64,816,576
Other Non Current Assets	$2,812,000	$1,365,000	$33,456,000	$1,581,465
Investmentin Financial Assets	$37,241,000	$30,824,000	$0	-
Current Assets	$217,520,000	$176,693,000	$329,912,000	$525,629,557
Prepaid Assets	$4,885,000	$2,123,000	$670,000	$6,824,171
Receivables	$1,793,000	$1,172,000	$1,833,000	$4,811,503
Other Receivables	$1,788,000	$130,000	$1,833,000	$3,623,411
Accrued Interest Receivable	$5,000	$1,042,000	$0	-
Cash Cash Equivalents And Short Term Investments	$210,842,000	$173,398,000	$311,727,000	$499,968,692
Cash And Cash Equivalents	$210,632,000	$68,263,000	$291,506,000	$465,845,086
Assets Held For Sale Current	-	$0	$15,682,000	-
Goodwill And Other Intangible Assets	-	-	$16,661,964	$40,795,733
Other Intangible Assets	-	-	$16,661,964	$17,231,893
Restricted Cash	-	-	$0	$14,025,191
Taxes Receivable	-	-	$662,472	$1,188,092
Inventory	-	-	-	$0
Accounts Receivable	-	-	-	$0
Allowance For Doubtful Accounts Receivable	-	-	-	$0
Gross Accounts Receivable	-	-	-	$0
Debt
Total Debt	$3,067,000	$3,882,000	$3,887,000	$10,868,639
Long Term Debt And Capital Lease Obligation	$2,176,000	$3,066,000	$3,261,000	$4,648,153
Current Debt And Capital Lease Obligation	$891,000	$816,000	$626,000	$6,220,486
Long Term Debt	-	-	$8,310,950	-
Current Debt	-	-	$4,227,915	$2,747,525
Liabilities
Total Liabilities Net Minority Interest	$29,581,000	$11,520,000	$126,338,000	$168,678,417
Total Non Current Liabilities Net Minority Interest	$2,687,000	$3,066,000	$68,194,000	$58,788,138
Other Non Current Liabilities	$511,000	-	-	-
Current Liabilities	$26,894,000	$8,454,000	$58,144,000	$109,890,279
Other Current Liabilities	$9,180,000	$106,000	$49,669,000	-
Payables And Accrued Expenses	$16,823,000	$7,532,000	$7,849,000	$101,480,440
Liabilities Heldfor Sale Non Current	-	$0	$50,975,000	-
Derivative Product Liabilities	-	$0	$13,852,000	$12,854,492
Non Current Deferred Liabilities	-	$0	$106,000	$41,285,493
Current Deferred Liabilities	-	$106,000	$1,581,977	$2,189,353
Payables	-	-	$11,975,284	$16,724,740
Other Payable	-	-	$7,029,597	$7,335,092
Equity
Common Stock Equity	$230,941,000	$201,160,000	$242,584,000	$421,767,716
Total Equity Gross Minority Interest	$230,941,000	$201,160,000	$242,584,000	$421,767,716
Stockholders Equity	$230,941,000	$201,160,000	$242,584,000	$421,767,716
Gains Losses Not Affecting Retained Earnings	$41,546,000	$33,384,000	$39,771,000	$30,987,781
Other Equity Adjustments	$41,546,000	$33,384,000	$39,771,000	$30,987,781
Retained Earnings	$-1,332,308,000	$-1,286,039,000	$-1,263,809,000	$-994,615,396
Long Term Equity Investment	-	-	$1,704,427	$4,471,468
Other
Treasury Shares Number	$5,362,497	$8,873,276	$8,460,067	-
Ordinary Shares Number	$265,377,891	$187,452,495	$185,613,662	$190,879,919
Share Issued	$270,740,388	$196,325,771	$194,073,729	$190,879,919
Tangible Book Value	$230,941,000	$201,160,000	$242,584,000	$380,971,983
Invested Capital	$230,941,000	$201,160,000	$242,584,000	$424,515,241
Working Capital	$190,626,000	$168,239,000	$271,768,000	$415,739,278
Capital Lease Obligations	$3,067,000	$3,882,000	$3,887,000	$8,121,114
Total Capitalization	$230,941,000	$201,160,000	$242,584,000	$421,767,716
Treasury Stock	$5,042,000	$6,225,000	$8,007,000	$3,079,878
Additional Paid In Capital	$1,526,718,000	$1,460,021,000	$1,474,610,000	$1,388,456,075
Capital Stock	$27,000	$19,000	$19,000	$19,132
Common Stock	$27,000	$19,000	$19,000	$19,132
Long Term Capital Lease Obligation	$2,176,000	$3,066,000	$3,261,000	$4,648,153
Current Capital Lease Obligation	$891,000	$816,000	$626,000	$3,472,961
Current Accrued Expenses	$16,823,000	$7,532,000	$7,849,000	$84,755,700
Investments And Advances	$37,241,000	$30,824,000	$0	$4,471,468
Available For Sale Securities	$37,241,000	$30,824,000	-	-
Net PPE	$2,949,000	$3,798,000	$5,554,000	$17,967,910
Gross PPE	$2,949,000	$3,798,000	$6,518,000	$26,893,888
Other Properties	$2,949,000	$3,798,000	$3,777,000	$16,853,739
Other Short Term Investments	$210,000	$105,135,000	$20,221,000	$34,123,607
Non Current Deferred Revenue	-	$0	$106,000	$41,285,493
Current Deferred Revenue	-	$106,000	$1,581,977	$2,189,353
Accumulated Depreciation	-	$-224,000	$-964,000	$-8,925,978
Leases	-	$0	$869,000	$5,417,216
Machinery Furniture Equipment	-	$425,000	$1,872,000	$3,721,682
Properties	-	$0	$0	$0
Line Of Credit	-	-	$4,227,915	$2,747,525
Dueto Related Parties Current	-	-	$4,945,687	$9,389,648
Goodwill	-	-	$0	$23,563,840
Construction In Progress	-	-	$0	$901,251
Other Inventories	-	-	-	-
Duefrom Related Parties Current	-	-	-	-

Fetched: 2026-06-23

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-20,604,000	$-52,717,000	$-72,861,000	$-51,673,000
Operating Activities
Operating Cash Flow	$-20,597,000	$-52,669,000	$-72,697,000	$-49,582,000
Cash Flow From Continuing Operating Activities	$-20,597,000	$-52,669,000	$-72,697,000	$-49,582,000
Operating Gains Losses	$-3,396,000	$-12,825,000	$12,522,000	$59,610,000
Investing Activities
Capital Expenditure	$-7,000	$-48,000	$-164,000	$-2,091,000
Investing Cash Flow	$104,965,000	$-136,015,000	$-15,164,000	$-5,180,000
Cash Flow From Continuing Investing Activities	$104,965,000	$-136,015,000	$-15,164,000	$-5,180,000
Financing Activities
Repurchase Of Capital Stock	$0	$-335,000	$-8,644,000	$-3,006,000
Issuance Of Capital Stock	$61,714,000	$0	$0	$0
Financing Cash Flow	$57,725,000	$-335,000	$-8,237,000	$3,912,000
Cash Flow From Continuing Financing Activities	$57,725,000	$-335,000	$-8,237,000	$3,912,000
Net Other Financing Charges	$-4,189,000	-	-	-
Net Common Stock Issuance	$61,714,000	$-335,000	$-8,644,000	$-3,006,000
Common Stock Issuance	$61,714,000	$0	$0	$0
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
End Cash Position	$210,632,000	$68,263,000	$310,667,000	$475,371,000
Beginning Cash Position	$68,263,000	$310,667,000	$475,371,000	$552,666,000
Effect Of Exchange Rate Changes	$276,000	$573,000	$5,197,000	$14,197,000
Changes In Cash	$142,093,000	$-242,977,000	$-169,901,000	$-91,492,000
Cash Flow From Discontinued Operation	$0	$-53,958,000	$-73,803,000	$-40,642,000
Proceeds From Stock Option Exercised	$200,000	$0	$407,000	$6,918,000
Common Stock Payments	$0	$-335,000	$-8,644,000	$-3,006,000
Net Investment Purchase And Sale	$104,925,000	$-136,029,000	$-15,000,000	$-3,089,000
Sale Of Investment	$154,885,000	$109,834,000	$85,000,000	$764,421,000
Purchase Of Investment	$-49,960,000	$-245,863,000	$-100,000,000	$-767,510,000
Net PPE Purchase And Sale	$40,000	$14,000	$-164,000	$-2,091,000
Sale Of PPE	$47,000	$62,000	$0	$0
Purchase Of PPE	$-7,000	$-48,000	$-164,000	$-2,091,000
Change In Working Capital	$17,074,000	$-2,811,000	$-37,122,000	$17,092,000
Change In Other Current Liabilities	$-304,000	$-694,000	$-1,469,000	$-991,000
Change In Payables And Accrued Expense	$18,081,000	$-213,000	$-35,681,000	$18,337,000
Change In Prepaid Assets	$-703,000	$-1,904,000	$28,000	$-1,800,000
Other Non Cash Items	$42,071,000	$12,388,000	-	$2,253,000
Stock Based Compensation	$5,974,000	$-1,949,000	$10,239,000	$13,149,000
Unrealized Gain Loss On Investment Securities	$5,164,000	$0	$-221,000	$-1,898,000
Asset Impairment Charge	$0	$1,246,000	$23,041,000	$0
Depreciation Amortization Depletion	$856,000	$978,000	$1,061,000	$1,415,000
Depreciation And Amortization	$856,000	$978,000	$1,061,000	$1,415,000
Depreciation	$856,000	$978,000	$1,061,000	$1,415,000
Earnings Losses From Equity Investments	$0	$1,038,000	$11,404,000	$64,707,000
Gain Loss On Investment Securities	$-3,412,000	$-13,852,000	$1,118,000	$-5,070,000
Gain Loss On Sale Of PPE	$16,000	$-11,000	$0	$-27,000
Net Income From Continuing Operations	$-88,340,000	$-49,696,000	$-82,217,000	$-141,203,000
Interest Paid Supplemental Data	-	$0	$99,314	$0
Income Tax Paid Supplemental Data	-	$0	$0	$103,000
Change In Receivables	-	$0	$0	$1,546,000
Changes In Account Receivables	-	$0	$0	$-2,755,000
Repayment Of Debt	-	-	$-6,902,068	$0
Issuance Of Debt	-	-	$16,766,780	$2,747,525
Net Issuance Payments Of Debt	-	-	$9,864,712	$2,747,525
Net Short Term Debt Issuance	-	-	$9,864,712	$2,747,525
Short Term Debt Payments	-	-	$-6,902,068	$0
Short Term Debt Issuance	-	-	$16,766,780	$2,747,525
Net Business Purchase And Sale	-	-	$-821,319	$0
Sale Of Business	-	-	$25,111	$0
Purchase Of Business	-	-	$-846,429	$0
Change In Other Working Capital	-	-	$2,506,701	$7,617,439
Change In Inventory	-	-	$0	$3,947,792
Amortization Cash Flow	-	-	$109,754	$112,765
Amortization Of Intangibles	-	-	$109,754	$112,765
Gain Loss On Sale Of Business	-	-	$1,115,171	$0
Net Long Term Debt Issuance	-	-	-	-
Long Term Debt Payments	-	-	-	-
Long Term Debt Issuance	-	-	-	-

Fetched: 2026-06-23